SEC Tracker
Get the app

Achieve Life Sciences ACHV

Achieve Life Sciences reports Q3 2026 results

Achieve Life Sciences (ACHV) filed an 8-K with the SEC on Nov 10, 2026, 4:04 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026
  2. Net loss for the three months ended September 30, 2026, was $12.1 million
  3. Completed three commercial-scale stability batches for U.S.-based finished drug product manufacturing
  4. NDA resubmission remains on track for the fourth quarter of 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Achieve Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.